VJOncology is committed to improving our service to you

GU Cancers 2018 | Immune checkpoint inhibitors for urothelial carcinoma: the current landscape

VJOncology is committed to improving our service to you

Thomas Powles

Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma, the most common type of bladder cancer. In this interview, Thomas Powles, MD, of Barts Cancer Institute, London, UK, gives us an overview of the use of these agents in patients who have failed platinum-based chemotherapy, as well as previously untreated patients. Prof. Powles discussing the promising agents, how they stack up against standard chemotherapy and key trials in this area. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter